“Ozambik Children”… a magic treatment for obesity that causes sudden pregnancies

In a new trend that many have dubbed “Ozmek babies,” a number of women have reported on social media that they have become pregnant after using weight-loss medications that mimic the hormone GLP-1 (glucagon-like peptide-1) such as “Ozmek,” which is famous as a “cure.” My magic for obesity.

Women reported on the TikTok platform that they had become pregnant after years of infertility. In a response post, a woman with the account name @dkalsolive shared that she said that she was suffering from infertility after her second cesarean section, and that she had also become pregnant four months after starting to take “Ozembic.”

However, others responded to the post, saying they got pregnant despite taking necessary precautions. An account called @haleyfriend11 said: “I also got pregnant after using (Ozambik) and was taking birth control pills!” She wrote: “The baby is due in June.” (June)”.

Although babies conceived while using the drug are often called “Ozambik babies,” some expectant mothers, like @Chelsea, have had success with other weight-loss drugs that mimic the GLP-1 hormone.

Another woman said: “I suffered from infertility for 8 years. “I started with Monjaro, and 10 months later I was pregnant with our miracle baby,” Healthline reported.

Injectable weight loss treatments such as Wigvoy and Ozambik amplify the effects of GLP-1 (glucagon-like peptide-1). It slows down the speed at which food passes through the stomach, making people feel full longer.

How do GLP medications work?

Dr. Neha Lalani, an endocrinologist from Austin, Texas, confirmed that this phenomenon is certainly real, and said: “We have witnessed cases of failure in oral contraceptives, as well as increased fertility using medications such as GLP-1 agonists.” ».

Regarding the failure of birth control pills, Lalani said, “It has to do with how GLP-1 agonists work, as well as GIP/GLP-1 agonists, as these drugs work to slow stomach emptying, and thus affect how food and medications are absorbed.”

She explained: “This causes oral contraceptive pills to not be absorbed continuously, especially every time the dose of GLP-1/GIP+ GLP-1 agonists is increased, and this leads to failure of oral contraceptive pills.”

Lalani advises people to use alternative methods of birth control when using these medications.

How can fertility be affected by medications such as Ozempic?

Regarding any direct effects on fertility, Lalani noted that more research is needed before we can determine how GLP-1 agonists affect reproductive function.

However, Lalani speculated that the effect may be due to the fact that these drugs cause weight loss. She said: “Increased fertility and sudden pregnancy have been well reported in previously infertile patients, even with minimal weight loss (about 5%), and with lifestyle modification in addition to other weight-loss medications.”

Lalani added that improvements in ovarian health resulting from weight loss may be able to restore ovarian function.

Dr. Jamie Griffo, director of the program at NYU Langone Fertility Center in New York City, agreed with this assessment, saying: “Many high BMI patients do not ovulate, some have polycystic ovary syndrome, and some have problems with ovulation. Many of them do not ovulate regularly.”

He explained: “With weight loss due to these medications, many anovulatory women begin to have regular ovulation and menstruation, which moves them from a state of low fertility to a state of more normal fertility.”

What is the effect of taking “Ozembic” on pregnancy?

Grifo added that there are serious risks to pregnancy when taking these medications, and women need to be closely monitored, especially if they are trying to get pregnant.

In this context, Novo Nordisk, the company that manufactures the brands Ozambik, Wigvoy, and the drug Semaglutide, which has been approved to treat type 2 diabetes and obesity, explained in a statement that it is not currently known how safe these drugs are. For use in pregnant women.

Women who were pregnant or trying to become pregnant were excluded from semaglutide trials, so there are not enough human data to determine whether semaglutide is associated with major birth defects, miscarriages, or adverse outcomes for either the mother or the child.

However, animal studies using Wigvoy suggest that there may be risks to its use. The study investigating the safety of Wigfoi during human pregnancy is ongoing and is not scheduled to be completed until August 2027.

Currently, the prescribing information for Ozempic states that the drug should be discontinued at least two months before pregnancy to allow sufficient time for the drug to be eliminated from the body.

Wigvoy offers a similar warning, while also stating that it may cause harm to the fetus and should be discontinued as soon as pregnancy is known.

The pharmaceutical company advised that “individual patient decisions should be made in collaboration with the healthcare provider, as part of a shared decision-making process.”

ظهرت في الأصل على aawsat.com

Leave a Comment